To view a list of publications by Dr. Ances via PubMed, click the button below. A new tab will appear, and you will be taken to the PubMed site.



Publications by Topic

View a complete list of publications by topic by Dr. Ances via PubMed, click the links below. A new tab will appear, and you will be taken to the PubMed site. Under each topic are the most recent publications.

HIV

Association of Immunosuppression and Viral Load With Subcortical Brain Volume in an International Sample of People Living With HIV

This cross-sectional study established the HIV Working Group within the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) consortium to pool and harmonize data from existing HIV neuroimaging studies

Collateral damage: Impact of SARS-CoV-2 pandemic in people living with HIV

People living with HIV (PLWH) may be at higher risk for adverse outcomes indirectly associated with the severe acute respiratory syndrome coronavirus (SARS-CoV-2). When comparing responses to questionnaires administered when social distancing and quarantine guidelines were first implemented, we found that PLWH were more likely to have restricted access to medical care, increased financial stress, increased symptoms of anxiety and depression, and increased substance use compared to demographically-similar people without HIV.

Effects of anticholinergic medication use on brain integrity in persons living with HIV and persons without HIV

This study examines relationships between anticholinergic (AC) medication burden and brain integrity in people living with HIV (PLWH) and people without HIV (HIV-).

Mindfulness-based stress reduction for HIV-associated neurocognitive disorder: Rationale and protocol for a randomized controlled trial in older adults

Mindfulness-based stress reduction (MBSR) has potential to improve neurocognitive performance, psychosocial wellbeing, and quality of life, but empirical studies in this growing vulnerable population are lacking. In this trial, participants who are living with HIV infection and continue to experience behavioral and cognitive symptoms of HAND, are randomized to MBSR.

Comparison of [11C]-PBR28 Binding Between Persons Living With HIV and HIV-Uninfected Individuals

Virologically suppressed PLWH on combined antiretroviral therapy and HIV-negative (HIV-) controls completed TSPO-PET imaging using the radiotracer [C]PBR28. Because of tracer complexity and differing procedures used in previous studies, we employed an expansive methodological approach, using binding potential (BP) and standard uptake value ratio and multiple different reference regions to estimate [C]PBR28 binding.

Machine Learning Analysis Reveals Novel Neuroimaging and Clinical Signatures of Frailty in HIV

Frailty is an important clinical concern for the aging population of people living with HIV (PLWH). The objective of this study was to identify the combination of risk features that distinguish frail from non-frail individuals. Machine learning analysis of highly dimensional risk features was performed on a clinical cohort of PLWH.

Medication management abilities are reduced in older persons living with HIV compared with healthy older HIV- controls

This study examined predictors of, and relationships between, objective (Medication Management Test-Revised (MMT-R)) and self-reported medication management ability in older (≥ 50 years) PLWH compared with HIV-uninfected (HIV-) individuals.

Deep Learning Analysis of Cerebral Blood Flow to Identify Cognitive Impairment and Frailty in Persons Living With HIV

Deep learning algorithms of cerebral blood flow were used to classify cognitive impairment and frailty in people living with HIV (PLWH). Feature extraction techniques identified brain regions that were the strongest predictors.

Altered neuropsychological performance and reduced brain volumetrics in people living with HIV on integrase strand transfer inhibitors

A cross-sectional analysis of PLWH on combined antiretroviral therapy aged more than 18 years at a single institution.


Alzheimer Disease

Modeling autosomal dominant Alzheimer’s disease with machine learning

Machine learning models were used to discover novel disease trajectories for autosomal dominant Alzheimer’s disease.

Leveraging molecular biomarkers to make the common diagnosis in the uncommon patient

The factors that predispose to relapse in patients recovering with autoimmune encephalitis (AE) are largely unknown, complicating efforts to distinguish patients with resurgent symptoms who may benefit from additional immune-modulating therapies from those with other causes of impairment.

Obesity and White Matter Neuroinflammation Related Edema in Alzheimer Disease Dementia Biomarker Negative Cognitively Normal Individuals

We assessed influence of obesity on neuroinflammation imaging that may mediate brain morphometric changes. Establishing the role of neuroinflammation in obesity will enhance understanding of this modifiable disorder as a risk factor for Alzheimer’s disease (AD) dementia.

Resting-State Functional Connectivity Disruption as a Pathological Biomarker in Autosomal Dominant Alzheimer Disease

Identified a global resting state functional connectivity (gFC) signature in mutation carriers (MC) from the Dominantly Inherited Alzheimer Network (DIAN). Assessed the gFC with regards to amyloid (A), tau (T), and neurodegeneration (N) biomarkers and estimated years to symptom onset (EYO).

Flortaucipir (tau) PET in LGI1 antibody encephalitis

The contributors to persistent cognitive impairment and hippocampal atrophy in leucine-rich glioma-inactivated 1 antibody encephalitis (LGI1) patients are unknown. We evaluated whether tau neuropathology measured with [18 F]flortaucipir PET neuroimaging associated with persistent cognitive impairment and hippocampal atrophy in four recovering LGI1 patients.

Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease

Since late-onset Alzheimer disease (LOAD) participants tend to have age-related comorbidities, the younger-onset age in autosomal dominant AD (ADAD) may provide a more idealized model of cortical thinning in AD. To test this, the goals of this study were to compare the degree of overlap between the ADAD and LOAD cortical thinning maps and to evaluate the ability of the ADAD cortical signature regions to predict early pathological changes in cognitively normal individuals.

Cerebrospinal fluid Aβ42 moderates the relationship between brain functional network dynamics and cognitive intraindividual variability

As Alzheimer’s disease (AD) pathology accumulates, resting-state functional connectivity (rs-fc) within and between brain networks decreases, and fluctuations in cognitive performance known as intraindividual variability (IIV) increase. Here, we assessed the relationship between IIV and anticorrelations in rs-fc between the default mode network (DMN)-dorsal attention network (DAN) in cognitively normal older adults and symptomatic AD participants.

Biphasic cortical macro- and microstructural changes in autosomal dominant Alzheimer’s disease

In this study we tested this model fitting linear versus quadratic trajectories and computed the timing of the inflection points vertexwise of cortical thickness and cortical diffusivity-a novel marker of cortical microstructure-changes in participants from the Dominantly Inherited Alzheimer Network.

Evaluating resting-state BOLD variability in relation to biomarkers of preclinical Alzheimer’s disease

We tested relationships between resting-state BOLD variability and biomarkers of amyloidosis, tauopathy, and neurodegeneration in a large, well-characterized sample of cognitively normal adults, using multivariate machine learning techniques.


Down syndrome

PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer’s disease progression in Down syndrome

Adults with Down syndrome (DS) are predisposed to Alzheimer’s disease (AD) and reveal early amyloid beta (Aβ) pathology in the brain. Positron emission tomography (PET) provides an in vivo measure of Aβ throughout the AD continuum. Due to the high prevalence of AD in DS, there is need for longitudinal imaging studies of Aβ to better characterize the natural history of Aβ accumulation, which will aid in the staging of this population for clinical trials aimed at AD treatment and prevention.

Plasma Total-Tau and Neurofilament Light Chain as Diagnostic Biomarkers of Alzheimer’s Disease Dementia and Mild Cognitive Impairment in Adults with Down Syndrome

This study aimed to investigate the cross-sectional diagnostic performance of plasma neurofilament light chain (Nf-L) and total-tau, individually and in combination among a cohort of DS adults.

Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NiAD) study at baseline

The goal of the present study was to assess the presence of brain tau using [18F]AV-1451 positron emission tomography (PET) in DS and to assess the relationship of brain tau pathology to Aβ using Pittsburgh Compound B (PiB)-PET.

The AT(N) framework for Alzheimer’s disease in adults with Down syndrome

The National Institute on Aging in conjunction with the Alzheimer’s Association (NIA-AA) recently proposed a biological framework for defining the Alzheimer’s disease (AD) continuum. This new framework is based upon the key AD biomarkers (amyloid, tau, neurodegeneration, AT[N]) instead of clinical symptoms and represents the latest understanding that the pathological processes underlying AD begin decades before the manifestation of symptoms. By using these same biomarkers, individuals with Down syndrome (DS), who are genetically predisposed to developing AD, can also be placed more precisely along the AD continuum.

The Alzheimer’s Biomarker Consortium-Down Syndrome: Rationale and methodology

We describe the development of a multi-center, longitudinal study of biomarkers of AD in DS. The protocol includes longitudinal examination of clinical, cognitive, blood and cerebrospinal fluid-based biomarkers, magnetic resonance imaging and positron emission tomography measures (at 16-month intervals), as well as genetic modifiers of AD risk and progression.

Proteomic profiles for Alzheimer’s disease and mild cognitive impairment among adults with Down syndrome spanning serum and plasma: An Alzheimer’s Biomarker Consortium-Down Syndrome (ABC-DS) study

Previously generated serum and plasma proteomic profiles were examined among adults with Down syndrome (DS) to determine whether these profiles could discriminate those with mild cognitive impairment (MCI-DS) and Alzheimer’s disease (DS-AD) from those cognitively stable (CS).

Adaptation of the Clinical Dementia Rating Scale for adults with Down syndrome

We adapted a widely used instrument, the Clinical Dementia Rating (CDR) Scale, which is a component of the Uniform Data Set used by all federally funded Alzheimer Disease Centers for use in adults with DS, and tested the instrument among 34 DS patients recruited from the community. The participants were assessed using two versions of the modified CDR-a caregiver questionnaire and an in-person interview involving both the caregiver and the DS adult. Assessment also included the Dementia Scale for Down Syndrome (DSDS) and the Raven’s Progressive Matrices to estimate IQ.

Publications by year

View a complete list of publications by year by Dr. Ances via PubMed, click the links below. A new tab will appear, and you will be taken to the PubMed site.